Thesis
60% ORR and 15-month PFS in non-classical EGFR NSCLC set up the pivotal bet — FDA alignment determines whether data converts to approval
Silevertinib posted 60% ORR and a preliminary 15.2-month median PFS in 43 frontline non-classical EGFR-mutant NSCLC patients, a genetically defined population historically excluded from approved TKIs. The thesis resolves on whether an FDA meeting in 2026 yields a pivotal path acceptable for approval, since the single-arm Phase 2 design leaves approvability dependent on regulatory agreement on endpoints and control. Cash through H2 2028 covers that meeting and preliminary GBM data, but a negative or inconclusive FDA response could stall pivotal initiation and force a redesign.
Focus
Silevertinib pivotal trial FDA meeting in H2 2026
Q4 2026
Bull
FDA alignment on a pivotal trial design — ideally a single-arm or randomized study with ORR or PFS as the primary endpoint — would confirm that the Phase 2 data package is registrationally credible and de-risk the path to approval. A positive outcome would likely include agreement on the target mutation population, sample size, and an accelerated approval framework, converting the strong Phase 2 efficacy signals into a clear regulatory roadmap and materially re-rating the stock.
Bear
FDA could require a randomized controlled trial against an active comparator rather than accepting a single-arm design, substantially increasing trial size, cost, and timeline beyond current cash runway. Alternatively, the agency may contest the breadth of the non-classical EGFR mutation definition or demand additional safety data on the 150 mg dose, delaying pivotal trial initiation and eroding confidence that the existing data package supports approval.
Unlock the full thesis for BDTX.
The living thesis log, full pipeline, competitive landscape, and the ability to ask anything — updated automatically as the story changes.
Start your 7-day free trialRelated companies
Generated automatically from SEC filings, trial readouts, and earnings calls. For informational purposes only. Not financial advice.